, Une étude Canadienne s'est intéressée à l'induction intraveineuse mais chez seulement un sous-groupe de 19 patients sur les 167 que comportait leur cohorte, avec un taux de réponse clinique à 3 mois de 57
20) ont démontré un bénéfice clinique à 3 mois (défini par l'amélioration des signes cliniques et des tests biologiques) de 65% chez des patients tous en échec d'au moins un anti-TNF et présentant une atteinte luminale de la maladie. De plus, la présence d'un traitement immunosuppresseur à l'induction était significativement reliée au bénéfice clinique à 3 mois (OR 5,43 ,
, Dans notre étude, les cinq patients sous immunosuppresseurs étaient en réponse clinique à la semaine 8 (soit 100% de réponse dans ce sous-groupe) mais aucun lien statistiquement significatif n'a pu être mis en évidence par manque de puissance. Pourtant, dans l'étude randomisée de phase III IM-UNITI(11), peu de patients présentaient des anticorps anti-ustekinumab à 44 semaines de traitement (2,3%) faisant discuter du réel
,
, Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review, Gastroenterology. janv, vol.142, issue.1, pp.46-54, 2012.
The global burden of IBD: from 2015 to 2025, Nat Rev Gastroenterol Hepatol. déc, vol.12, issue.12, pp.720-727, 2015. ,
Understanding and Preventing the Global Increase of ,
, Inflammatory Bowel Disease. Gastroenterology. févr, vol.152, issue.2, pp.313-321, 2017.
Peyrin-Biroulet L. Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease, Expert Opin Biol Ther, vol.16, issue.10, pp.1277-90, 2016. ,
,
Selecting Therapeutic Targets in Inflammatory Bowel Disease ,
, Determining Therapeutic Goals for Treat-to-Target, Am J Gastroenterol. sept, vol.110, issue.9, pp.1324-1362, 2015.
,
, Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study, Gut. avr, vol.58, issue.4, pp.501-509, 2009.
,
, Adalimumab safety in global clinical trials of patients with Crohn's disease, Inflamm Bowel Dis. sept, vol.15, issue.9, pp.1308-1327, 2009.
,
, Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety, Inflamm Bowel Dis. 19 mars, vol.24, issue.4, pp.849-60, 2018.
,
, Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed, Gastroenterology. sept, vol.147, issue.3, pp.618-627, 2014.
Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders, mAbs. déc, vol.3, issue.6, pp.535-580, 2011. ,
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease, N Engl J Med, vol.17, issue.20, pp.1946-60, 2016. ,
, Recommandation temporaire d'utilisation STELARA, HAS, 2015.
Avis de la Commission de la Transparence sur l'ustekinumab ,
,
, Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology, Can J Gastroenterol J Can Gastroenterol. sept, vol.19, 2005.
A simple index of Crohn's-disease activity, Lancet Lond Engl. 8 mars, vol.1, issue.8167, p.514, 1980. ,
,
, Ustekinumab induction and maintenance therapy in refractory Crohn's disease, N Engl J Med, vol.367, issue.16, pp.1519-1547, 2012.
Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease--the McGill experience, J Crohns Colitis, vol.8, issue.11, pp.1516-1538, 2014. ,
,
, Ustekinumab for the Treatment of Refractory Crohn's Disease: The Spanish Experience in a Large Multicentre Open-label Cohort, Inflamm Bowel Dis, vol.22, issue.7, pp.1662-1671, 2016.
, endoscopic and radiographic outcomes with ustekinumab in medically-refractory
, Crohn's disease: real world experience from a multicentre cohort, Aliment Pharmacol Ther, vol.45, issue.9, pp.1232-1275, 2017.
Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's ,
URL : https://hal.archives-ouvertes.fr/hal-01214012
, Disease Refractory to Anti-Tumor Necrosis Factor Agents, Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. févr, vol.14, issue.2, pp.242-250, 2016.
,
, Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up, Br J Dermatol. avr, vol.168, issue.4, pp.844-54, 2013.
Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry, J Am Acad Dermatol, vol.77, issue.5, pp.845-854, 2017. ,